Nov 13, 2023
Ymmunobio is attending the 8th Investival Showcase in London!
May 3, 2023
Dr. Schiemann presents at the Biotech Forum on innovative treatments using new classes of antibodies
Focus on the mechanism of action of anti-tumor activity for lead asset YB-200
Apr 24, 2023
Ymmunobio team represents Ymmunobio for Swiss Biotech Day 2023
Nov 11, 2022
Ymmunobio Presented Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200
Oct 25, 2022
Ymmunobio at the "Gateway to the Global Biopharma Community"